The Efficacy of N-acetylcysteine as an Adjunctive Treatment in Bipolar Depression: A Double-blind, Randomised, Placebo-controlled Trial

N-乙酰半胱氨酸辅助治疗双相抑郁症的功效：双盲、随机、安慰剂对照试验

• 批准号: nhmrc : 1026307
• 负责人: A/Pr Seetal Dodd
• 金额: $ 64.69万
• 依托单位: Deakin University
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2012
• 资助国家: 澳大利亚
• 起止时间: 2012-01-01 至 2016-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/efficacy-n-acetylcysteine-controlled-trial/110486
• 关键词: Efficacy; acetylcysteine; Adjunctive; Treatment; Bipolar

The brain's antioxidant defences, particularly glutathione, are reduced in bipolar disorder. Treatment with N-acetylcysteine (NAC), a naturally occurring and well-tolerated glutathione precursor, has been shown by our research group to be effective at reducing depression in people with bipolar disorder during a 6-month pilot trial. In this definitive placebo controlled randomised study, we aim to see if add-on treatment with NAC can reduce depression in participants in the depressive phase of bipolar disorder.

大脑的抗氧化防御，尤其是谷胱甘肽，在双相情感障碍中会降低。n -乙酰半胱氨酸（NAC）是一种天然存在且耐受性良好的谷胱甘肽前体，我们的研究小组在为期6个月的试点试验中显示，它可以有效地减少双相情感障碍患者的抑郁症。在这项明确的安慰剂对照随机研究中，我们的目标是观察NAC的附加治疗是否可以减少双相情感障碍抑郁期参与者的抑郁。